9MW 1411
Alternative Names: 9MW1411; 9MW1411 - Mabwell Biosciences; MW 14Latest Information Update: 28 May 2024
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Anti-infectives; Antibacterials; Monoclonal antibodies
- Mechanism of Action Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Staphylococcal infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Staphylococcal-infections(In volunteers) in China (IV)
- 16 Feb 2022 Phase-II clinical trials in Staphylococcal infections (In adults, In the elderly, Combination therapy) in China (IV) (NCT05339802)
- 16 Apr 2021 Phase-I clinical trials in Staphylococcal infections (In volunteers) in China (IV) (NCT04784312)